Bristol-Myers Squibb recalls Avalide due to reduced effectiveness

January 17, 2011

Bristol-Myers Squibb Co. recently recalled 64 million tablets of Avalide blood pressure medication in the United States and Puerto Rico.

Bristol-Myers Squibb Co. recently recalled 64 million tablets of Avalide blood pressure medication in the United States and Puerto Rico.

The manufacturer recalled the lots manufactured in plants in Puerto Rico and Indiana because of the potential for reduced effectiveness, according to a Reuters report. Bristol-Myers Squibb said there was potential variability in levels of the less-soluble form of the active ingredient irbesartan.

Avalide is a combination of the drugs irbesartan, sold under the brand name Avapro, and hydrochlorothiazide. Bristol-Myers Squibb also recalled 60 million tablets of Avalide in September 2010.

Bristol-Myers Squibb communicated the January recall via letters to wholesalers and healthcare professionals, but not publicly, according to Reuters.

Meanwhile, Bristol-Myers Squibb will announce its fourth quarter and fiscal year 2010 financial results on January 27.